Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
French researchers have found that a protein-bound uremic toxin, p-cresyl sulfate (PCS), contributes to the development of insulin resistance in mice, providing a new potential therapeutic target for treating chronic kidney disease (CKD), they say.
"We demonstrate that PCS administered to mice with normal renal function induces insulin resistance and metabolic disturbances mimicking those reported in CKD," remark Christophe Soulage (INSERM, Lyon) and colleagues.
The PCS toxin circulates in the blood as a conjugate of p-cresol, which is produced in the gut by the putrefactive bacteria of the gut microbiota. Interestingly, the team found that reducing p-cresol production with the use of a prebiotic reduced PCS levels and prevented insulin resistance and dyslipidemia in the model.
http://www.news-medical.net/news/20130104/Toxin-induced-insulin-resistance-combated-in-mice.aspx
"We demonstrate that PCS administered to mice with normal renal function induces insulin resistance and metabolic disturbances mimicking those reported in CKD," remark Christophe Soulage (INSERM, Lyon) and colleagues.
The PCS toxin circulates in the blood as a conjugate of p-cresol, which is produced in the gut by the putrefactive bacteria of the gut microbiota. Interestingly, the team found that reducing p-cresol production with the use of a prebiotic reduced PCS levels and prevented insulin resistance and dyslipidemia in the model.
http://www.news-medical.net/news/20130104/Toxin-induced-insulin-resistance-combated-in-mice.aspx